紫杉醇新辅助化疗单周方案与密集方案治疗乳腺癌的疗效和安全性

Efficacy and safety of one-week paclitaxel neoadjuvanttchemotherapy versus intensive chemotherapy in the treatment of breast cancer

目的比较紫杉醇新辅助化疗单周方案和密集方案对乳腺癌患者的疗效和安全性。方法回顾性研究2021年3月至2023年3月在驻马店市中心医院就诊的68例乳腺癌患者的临床资料。将其分为两组,每组34例。研究组接受紫杉醇新辅助化疗单周方案,对照组接受传统的密集方案。比较两种方案在病理学完全缓解率、肿瘤标志物水平、不良反应方面的差异。结果两组患者的临床治疗总有效率比较,差异未见统计学意义(P=0.215)。研究组患者的病理完全缓解率明显高于对照组(P=0.027)。两组患者治疗结束后肿瘤标志物水平比较,差异未见统计学意义(P>0.05)。在不良反应方面,研究组患者恶心呕吐发生率显著低于对照组(P=0.007),中性粒细胞减少发生率高于对照组(P=0.013)。结论紫杉醇新辅助化疗单周方案在乳腺癌患者病理学完全缓解率方面更优,不良反应更少。

Objectivee To compare the efficacy and safety of weekly versus dose-dense paclitaxel neoadjuvant chemotherapy in breast cancer patients.Methods The clinical data of 68 patients with breast cancer treated in Zhumadian Central Hospital from March 2021 to March 2023 were retrospectively studied.They were divided into two groups,with 34 cases in each group.The study group received a one-week regimen of paclitaxel neoadjuvant chemotherapy,while the control group received a traditional intensive regimen.The differences in pathological complete response rates,levels of tumor markers and adverse reactions were compared between the two regimens.ResulstsThere was no significant difference in the total effective rate between the two groups(P=0.215).The pathological complete response rate of the study group was significantly higher than that of the control group(P=0.027).There was no significant difference in the levels of tumor markers between the two groups after treatment(P>0.05).In terms of quality of life during treatment,the study group had better quality of life(P<0.05).The incidence of nausea and vomiting in the study group was significantly lower than that in the control group(P=0.007),and the incidence of neutropenia in the study group was higher than that in the control group(P=0.013).Conclusions Weekly paclitaxel neoadjuvant chemotherapy has a better pathological complete response rate,fewer adverse reactions in the treatment of breast cancer.